Oncology

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.

GC012F recently showed efficacy in newly-diagnosed MM in investigator-initiated trials.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.

Review top news and interview highlights from the week ending February 3, 2023.

Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.

Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.

The professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Mesoblast is resubmitting its BLA with new CMC, survival, and mechanism of action data on the therapy and phase 3 trial.

AB-101 is also being investigated with the innate cell engager AFM13 for CD30 lymphomas.

Positive preclinical data related to SENTI-202 and SENTI-401 were presented at conferences last year.

There were no deaths or safety signals identified by the DSMB for the 3 treated patients in cohort 1.

Sana Biotechnology also plans to submit another IND for the same indications for a CD22-targeted CAR T later in 2022.

The phase 1 portion of the trial assessing CNA3103 will start enrollment in Australia in the first half of 2023; the phase 2 portion will expand to the US.

Cilta-cel demonstrated a significant improvement in progression-free survival over standards of care.

Review top news and interview highlights from the week ending January 27, 2023.

The chief executive officer and president of Eterna Therapeutics discussed the company’s new collaboration with the University of Texas MD Anderson Cancer Center.

No dose-limiting toxicities were observed at 28 days of follow-up.

Breyanzi is currently approved for the second-line or later treatment of large B-cell lymphomas.

Iovance is on track to complete its rolling BLA submission for lifileucel in the post-anti-PD1 melanoma indication in the first quarter of 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The CD19/CD20 dual-targeted CAR is currently under investigation in an investigator-initiated study in UCLA.

The dosing of the first patient took place in December 2022 and no adverse events related to the therapy have been reported.

The FAD has granted primary IND clearance to the company’s T-Plex program and 2 initial TCR-T therapies.

With confidence building, numerous cell and gene therapies will likely go before the FDA and other global regulatory agencies this year, in addition to key data readouts.